Total results1,200
Search criteria
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.70High >= 0.60Medium >= 0.40Low >= 0.30| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| ADCK5 | Q3MIX3 | Uncharacterized aarF domain-containing protein kinase 5 (EC 2.7.11.-) | EnzymesPredicted membrane proteins | 1 | Other mediation | 1 | 0.40 | |||
| ANPRC | P17342 | Atrial natriuretic peptide receptor 3 (Atrial natriuretic peptide clearance receptor) (Atrial natriuretic peptide receptor type C) (ANP-C) (ANPR-C) (NPR-C) | Disease related genesPredicted intracellular proteinsPredicted membrane proteins | 1 | Heart failure | Clinical-translation mediationImmune mediationMetabolism mediation | 1 | 0.40 | ||
| AT10D | Q9P241 | Phospholipid-transporting ATPase VD (EC 7.6.2.1) (ATPase class V type 10D) (P4-ATPase flippase complex alpha subunit ATP10D) | EnzymesPredicted membrane proteinsTransporters | 10 | Fusion and delivery mediation | 1 | 0.40 | |||
| AT1A1 | P05023 | Sodium/potassium-transporting ATPase subunit alpha-1 (Na(+)/K(+) ATPase alpha-1 subunit) (EC 7.2.2.13) (Sodium pump subunit alpha-1) | Cancer-related genesDisease related genesEnzymes | 10 | Charcot-Marie-Tooth diseaseEpilepsyIntellectual disability | Clinical-translation mediationFusion and delivery mediation | 1 | 0.40 | ||
| AT1A3 | P13637 | Sodium/potassium-transporting ATPase subunit alpha-3 (Na(+)/K(+) ATPase alpha-3 subunit) (EC 7.2.2.13) (Na(+)/K(+) ATPase alpha(III) subunit) (Sodium pump subunit alpha-3) | Disease related genesEnzymesHuman disease related genes | 10 | DeafnessDystoniaEpilepsy | Clinical-translation mediationFusion and delivery mediation | 1 | 0.40 | ||
| AT1B1 | P05026 | Sodium/potassium-transporting ATPase subunit beta-1 (Sodium/potassium-dependent ATPase subunit beta-1) | Metabolic proteinsPredicted intracellular proteinsPredicted membrane proteins | 1 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.40 | |||
| AT2A2 | P16615 | Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) (SR Ca(2+)-ATPase 2) (EC 7.2.2.10) (Calcium pump 2) (Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform) (Endoplasmic reticulum class 1/2 Ca(2+) ATPase) | Disease related genesEnzymesEssential proteins | 10 | EpilepsyAsthmaHeart failure | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.40 | ||
| AT2B1 | P20020 | Plasma membrane calcium-transporting ATPase 1 (EC 7.2.2.10) (Plasma membrane calcium ATPase isoform 1) (PMCA1) (Plasma membrane calcium pump isoform 1) | Disease related genesEnzymesFDA approved drug targets | 10 | Intellectual disability | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.40 | ||
| AT2B3 | Q16720 | Plasma membrane calcium-transporting ATPase 3 (PMCA3) (EC 7.2.2.10) (Plasma membrane calcium ATPase isoform 3) (Plasma membrane calcium pump isoform 3) | Cancer-related genesDisease related genesEnzymes | 10 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.40 | |||
| AT2C2 | O75185 | Calcium-transporting ATPase type 2C member 2 (ATPase 2C2) (EC 7.2.2.10) (Ca(2+)/Mn(2+)-ATPase 2C2) (Secretory pathway Ca(2+)-transporting ATPase type 2) (SPCA2) | EnzymesFDA approved drug targetsMetabolic proteins | 10 | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 1 | 0.40 |